PROTHERA BIOLOGICS, LLC

Company Information
Address 349 Eddy Street
PROVIDENCE, RI, 02903-


Information

DUNS: 140315248

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    Amount: $984,466.00

    Neonatal hypoxia ischemia HI remains a major cause of acute perinatal brain injury leading ultimately to neurologic dysfunction manifesting as cerebral palsy mental retardation and epilepsy Unfo ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Therapeutic Role of Inter-alpha Inhibitors in Wound Healing

    Amount: $224,688.00

    DESCRIPTION provided by applicant Wound healing is an intricately regulated process broadly characterized by phases of inflammation proliferation and remodeling Imbalances in any one of these ph ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  3. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    Amount: $203,226.00

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, ...

    SBIRPhase I2014Department of Health and Human Services
  4. Rapid detection of neonatal sepsis

    Amount: $498,061.00

    DESCRIPTION (provided by applicant): The primary goal of this proposed research is to develop a rapid point-of-care (POC) test that can be used to identify neonatal sepsis in high-risk infants in a si ...

    SBIRPhase I2012Department of Health and Human Services
  5. Role of Inter-alpha Inhibitors in Anthrax Intoxication

    Amount: $2,679,880.00

    DESCRIPTION (provided by applicant): Anthrax is recognized as a class A bio-threat microbial pathogen that is readily weaponized and exceedingly difficult to treat. This bacterium is highly virulent i ...

    STTRPhase II2010Department of Health and Human Services
  6. Bioprocessing of Plasma Therapeutic Proteins using Sequential Affinity Monolithic

    Amount: $170,547.00

    DESCRIPTION (provided by applicant): Plasma fractionation is one of the largest industry segments in global therapeutic protein manufacture. The United States plays an important role in this industry ...

    SBIRPhase I2007Department of Health and Human Services
  7. Role of Inter-alpha Inhibitors in Anthrax Intoxication

    Amount: $1,000,000.00

    DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor proteins (lalp) as an effective protective agent against exp ...

    STTRPhase I2006Department of Health and Human Services
  8. Inter-alpha Inhibitors in Detecting CNS Cancer

    Amount: $139,911.00

    DESCRIPTION (provided by applicant) The overall goal is to develop a marketable novel predictive marker based on inter-alpha inhibitor proteins (laIp) in cerebrospinal fluid (CSF) that can be utili ...

    SBIRPhase I2005Department of Health and Human Services
  9. THERAPEUTIC USE OF INTER-ALPHA INHIBITOR IN SEPSIS

    Amount: $1,501,420.00

    DESCRIPTION (provided by applicant): The goal of the proposed research is to demonstrate that Inter-alpha serine protease inhibitor proteins (IaIp) are an effective therapy for sepsis. In sepsis, n ...

    SBIRPhase II2004Department of Health and Human Services
  10. Predictive value of inter-alpha inhibitors in sepsis

    Amount: $131,233.00

    DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor as a novel predictive marker for adult and newborn sepsis ...

    SBIRPhase I2003Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government